摘要
Research Article6 November 2017Open Access Source DataTransparent process SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis Varinder S Athwal Varinder S Athwal Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author James Pritchett James Pritchett School of Healthcare Science, Manchester Metropolitan University, Manchester, UK Search for more papers by this author Jessica Llewellyn Jessica Llewellyn Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Search for more papers by this author Katherine Martin Katherine Martin Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Elizabeth Camacho Elizabeth Camacho Centre for Health Economics, Institute of Population Health, Faculty of Medical & Human Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Search for more papers by this author Sayyid MA Raza Sayyid MA Raza Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Alexander Phythian-Adams Alexander Phythian-Adams Manchester Centre for Collaborative Inflammation Research, Faculty of Life Sciences, University of Manchester, Manchester, UK Search for more papers by this author Lindsay J Birchall Lindsay J Birchall Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Aoibheann F Mullan Aoibheann F Mullan Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Kim Su Kim Su Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Laurence Pearmain Laurence Pearmain Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Grace Dolman Grace Dolman Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK Search for more papers by this author Abed M Zaitoun Abed M Zaitoun Department of Cellular Pathology, Nottingham Digestive Diseases Centre and National Institute of Health Research Biomedical Research Unit in Gastroenterology and Liver Disease, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK Search for more papers by this author Scott L Friedman Scott L Friedman Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA Search for more papers by this author Andrew MacDonald Andrew MacDonald orcid.org/0000-0002-5356-1149 Manchester Centre for Collaborative Inflammation Research, Faculty of Life Sciences, University of Manchester, Manchester, UK Search for more papers by this author William L Irving William L Irving Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK School of Life Sciences, Nottingham Digestive Diseases Centre and National Institute of Health Research Biomedical Research Unit in Gastroenterology and Liver Disease, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK Search for more papers by this author Indra N Guha Indra N Guha Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK Search for more papers by this author Neil A Hanley Neil A Hanley Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Karen Piper Hanley Corresponding Author Karen Piper Hanley [email protected] orcid.org/0000-0001-9473-9647 Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Varinder S Athwal Varinder S Athwal Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author James Pritchett James Pritchett School of Healthcare Science, Manchester Metropolitan University, Manchester, UK Search for more papers by this author Jessica Llewellyn Jessica Llewellyn Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Search for more papers by this author Katherine Martin Katherine Martin Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Elizabeth Camacho Elizabeth Camacho Centre for Health Economics, Institute of Population Health, Faculty of Medical & Human Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Search for more papers by this author Sayyid MA Raza Sayyid MA Raza Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Alexander Phythian-Adams Alexander Phythian-Adams Manchester Centre for Collaborative Inflammation Research, Faculty of Life Sciences, University of Manchester, Manchester, UK Search for more papers by this author Lindsay J Birchall Lindsay J Birchall Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Aoibheann F Mullan Aoibheann F Mullan Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Kim Su Kim Su Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Laurence Pearmain Laurence Pearmain Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Grace Dolman Grace Dolman Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK Search for more papers by this author Abed M Zaitoun Abed M Zaitoun Department of Cellular Pathology, Nottingham Digestive Diseases Centre and National Institute of Health Research Biomedical Research Unit in Gastroenterology and Liver Disease, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK Search for more papers by this author Scott L Friedman Scott L Friedman Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA Search for more papers by this author Andrew MacDonald Andrew MacDonald orcid.org/0000-0002-5356-1149 Manchester Centre for Collaborative Inflammation Research, Faculty of Life Sciences, University of Manchester, Manchester, UK Search for more papers by this author William L Irving William L Irving Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK School of Life Sciences, Nottingham Digestive Diseases Centre and National Institute of Health Research Biomedical Research Unit in Gastroenterology and Liver Disease, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK Search for more papers by this author Indra N Guha Indra N Guha Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK Search for more papers by this author Neil A Hanley Neil A Hanley Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Karen Piper Hanley Corresponding Author Karen Piper Hanley [email protected] orcid.org/0000-0001-9473-9647 Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Search for more papers by this author Author Information Varinder S Athwal1,2,‡, James Pritchett3,‡, Jessica Llewellyn1, Katherine Martin1,2, Elizabeth Camacho4, Sayyid MA Raza1,2, Alexander Phythian-Adams5, Lindsay J Birchall1,2, Aoibheann F Mullan1,2, Kim Su1,2, Laurence Pearmain1,2, Grace Dolman6, Abed M Zaitoun7, Scott L Friedman8, Andrew MacDonald5, William L Irving6,9, Indra N Guha6, Neil A Hanley1,2 and Karen Piper Hanley *,1,2 1Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine & Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK 2Research & Innovation Division, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK 3School of Healthcare Science, Manchester Metropolitan University, Manchester, UK 4Centre for Health Economics, Institute of Population Health, Faculty of Medical & Human Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK 5Manchester Centre for Collaborative Inflammation Research, Faculty of Life Sciences, University of Manchester, Manchester, UK 6Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK 7Department of Cellular Pathology, Nottingham Digestive Diseases Centre and National Institute of Health Research Biomedical Research Unit in Gastroenterology and Liver Disease, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK 8Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA 9School of Life Sciences, Nottingham Digestive Diseases Centre and National Institute of Health Research Biomedical Research Unit in Gastroenterology and Liver Disease, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK ‡These authors contributed equally to this work *Corresponding author. Tel: +44 161 3060643; E-mail: [email protected] EMBO Mol Med (2017)9:1696-1710https://doi.org/10.15252/emmm.201707860 PDFDownload PDF of article text and main figures. Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Abstract Fibrosis and organ failure is a common endpoint for many chronic liver diseases. Much is known about the upstream inflammatory mechanisms provoking fibrosis and downstream potential for tissue remodeling. However, less is known about the transcriptional regulation in vivo governing fibrotic matrix deposition by liver myofibroblasts. This gap in understanding has hampered molecular predictions of disease severity and clinical progression and restricted targets for antifibrotic drug development. In this study, we show the prevalence of SOX9 in biopsies from patients with chronic liver disease correlated with fibrosis severity and accurately predicted disease progression toward cirrhosis. Inactivation of Sox9 in mice protected against both parenchymal and biliary fibrosis, and improved liver function and ameliorated chronic inflammation. SOX9 was downstream of mechanosignaling factor, YAP1. These data demonstrate a role for SOX9 in liver fibrosis and open the way for the transcription factor and its dependent pathways as new diagnostic, prognostic, and therapeutic targets in patients with liver fibrosis. Synopsis The extent of SOX9 detection in liver correlates with the severity of fibrosis and predicts its progression toward cirrhosis in patients with chronic liver disease. In mice, SOX9 loss improves scarring and ameliorates liver function and inflammation. Mechanosensitive signaling regulates SOX9 via YAP1; SOX9 regulates multiple components of the ECM in liver myofibroblasts. In rodent models of liver fibrosis Sox9 loss reduced scarring, improved liver function and blocked macrophage maturation resulting in fewer F4/80-positive macrophages. In patients, the profile of SOX9 detection following liver injury was identical to that observed in mouse. Prevalence of SOX9 expression in biopsies from patients with chronic liver disease correlated precisely with fibrosis severity. The extent of SOX9 in patients with early stages of liver disease predicted progression within 3 years and performed better than other associated fibrosis risk factors. Introduction In response to inflammation, the secretion of collagen-rich pathological extracellular matrix (ECM) by liver myofibroblasts, called hepatic stellate cells (HSCs), destroys normal tissue architecture and causes fibrosis. Fibrosis occurs in both hepatic parenchymal and biliary diseases and is a major cause of morbidity and mortality against which there are no approved drug treatments (Iredale, 2007; Friedman, 2008; Lee & Friedman, 2011; Lee et al, 2015). Even after withdrawal of the inflammatory insult, fibrosis can progress unchecked to organ failure and death. Alternatively, in some individuals liver fibrosis may not advance despite persisting insult (Ellis & Mann, 2012; Kisseleva et al, 2012; Troeger et al, 2012). Addressing this uncertainty requires in vivo knowledge of the molecular mechanisms that regulate fibrosis. The transcription factor sex determining region Y box 9 (SOX9) is responsible in vivo for the organized deposition of collagen as part of cartilage formation. In humans, mutations in the SOX9 gene cause the haploinsufficiency disorder campomelic dysplasia (CD), characterized by failed chondrogenesis (Foster et al, 1994; Wagner et al, 1994; Pritchett et al, 2011). In the liver, SOX9 is ordinarily expressed in cholangiocytes lining the bile ducts and plays roles in bile duct development and in hepatic regeneration (Antoniou et al, 2009; Carpentier et al, 2011; Yanger et al, 2013; Tarlow et al, 2014; Font-Burgada et al, 2015; Jors et al, 2015; Lu et al, 2015). In vitro, we have shown that SOX9 becomes expressed during the activation of HSCs by profibrotic signaling factors when it promotes production of ECM components, such as type 1 collagen (COL1) and osteopontin (OPN) (Hanley et al, 2008; Pritchett et al, 2012). However, these studies relied on imperfect in vitro cell models. Direct in vivo evidence for SOX9 function in liver fibrosis (rather than regeneration) has been lacking. In this study, we have studied SOX9 in patients with chronic liver disease where sequential liver biopsies enabled fibrosis severity and disease progression to be deciphered over time and examined the consequences of inactivating SOX9 in rodent models of parenchymal and biliary liver fibrosis. Results SOX9 profile in the liver of patients with chronic liver disease Patients chronically infected with hepatitis C virus (HCV) show variable severity of liver fibrosis with the potential for marked disease progression within a few years. While these patients are now routinely treated with antiviral drugs, this clinical setting offered a distinctive opportunity to study SOX9 and fibrosis progression because previous routine surveillance entailed patients undergoing accurately staged serial biopsies from their liver. We accessed the UK Trent HCV Cohort and identified 115 patients with initial and follow-up biopsy categorized for severity by a histopathologist using the 7-point Ishak (IS) fibrosis stage, IS0 to IS6; the latter representing the most severe fibrosis/cirrhosis (Ishak et al, 1995) (Table EV1). 70% of patients had no or mild fibrosis on initial biopsy (IS0-1; n = 80) rather than more intermediate (IS2-3; 16%, n = 19) or severe disease (IS4-6; 14%, n = 16). However, at follow-up biopsy 36.9 ± 2.5 months later, this percentage declined to 54% (n = 62) with corresponding increases in both the IS2-3 category (24%, n = 28) and severe (22%, n = 25) fibrosis. Thus, over 3 years liver fibrosis had progressed in 30 patients (26%), regressed in eight patients (7%), and remained unchanged in 77 (67%) allowing us to correlate SOX9 with severity (tissue remained from 152 biopsies for this purpose; Fig EV1) and disease progression (where tissue remained from 59 paired biopsies; Fig EV1). Click here to expand this figure. Figure EV1. Patient flowchart for biopsy selection Download figure Download PowerPoint Staining for collagen using picrosirius red (PSR) and αSMA (a marker of activated myofibroblasts) was increased with higher Ishak fibrosis stage particularly in regions of scarring (Fig 1A and B). In IS0 (no liver fibrosis), SOX9 was observed in the nuclei of cholangiocytes (Fig 1B; Antoniou et al, 2009; Rowe et al, 2013). In moderate and severe fibrosis, nuclear SOX9 was progressively more noticeable in cells with elongated nuclei and αSMA. SOX9 was also detected at slightly lower levels in cells with large round nuclei adjacent to the scar costained for the hepatocyte marker, α1-antitrypsin (α1AT), consistent with regenerative hepatocytes (termed Hep from here on) (Fig 1B and C). SOX9 was present in all CK19+ and CK7+ cholangiocytes lining bile ducts; these cells were not detected outside of duct structures. SOX9 was not detected in the CD34+ vasculature. Given the role of SOX9 in regenerative hepatocytes (Kawaguchi, 2013), we studied EpCAM which marks cholangiocytes and nascent hepatocytes (Yoon et al, 2011) and compared this to the SOX9+ ductal plate in human fetal liver, which gives rise to periportal hepatocytes and biliary cells (Carpentier et al, 2011; Furuyama et al, 2011; Rowe et al, 2013). In moderate and severe fibrosis, EpCAM localized to the SOX9+ Heps adjacent to the scar in an arrangement remarkably similar to the fetal ductal plate (Fig 1D). Thus, SOX9 could be partitioned discretely into bile duct nuclei and post-injury expression in isolated cells demarcating a putative HSC/Hep population. Figure 1. SOX9 in human liver fibrosis A. Liver biopsies showing no (IS0), moderate (IS3), and severe (IS6) fibrosis stained by PSR. Size bar, 300 μm. B. Immunohistochemistry (brown staining) for αSMA and SOX9 on consecutive sections from patients with no (IS0), moderate (IS3), and severe (IS6) fibrosis. Boxed areas are shown to the right at higher magnification. Bile duct (bd). SOX9 detected in HSCs with elongated nuclei (hatched line) next to scar and in hepatocytes with rounded nuclei (arrows). Size bars, 200 μm. C. Immunofluorescence for SOX9 (red) costained with CK19, CK7, α1AT, and αSMA (green). Arrowheads show elongated nuclei in αSMA-positive HSCs. D. Immunohistochemistry for SOX9 and EpCAM (brown staining) on consecutive sections from severe (IS6) fibrosis and normal fetal liver at 18 weeks post-conception (wpc). Dual immunofluorescence confirms SOX9 and EpCAM in the same cell in severe fibrosis. E–G. Data for SOX9 index for the biliary, HSC/Hep, and total (biliary + HSC/Hep) populations. In worsening categories of liver fibrosis (E). In the initial biopsy plotted against the increment in Ishak fibrosis stage between the initial and follow-up biopsy (F). The lines show the best fit by ordinal logistic regression analysis. In the initial biopsy categorized by whether patients did or did not progress by at least two stages on follow-up biopsy (G). H. Receiver operator curves for the sensitivity and specificity of the SOX9 index in the initial biopsy as a predictor of non-progressors and progressors. I–L. Plots of SOX9 index (total, HSC/Hep, and biliary) and NI score marking progressors in green and non-progressors in red. The solid line indicates the mean in each graph. The broken line in NI dot plot (L) indicates the threshold (score = 8) below which all NI is categorized as “mild”. Data information: Unless otherwise indicated in text, two-tailed unpaired t-test was used for statistical analysis. Data in bar charts show means ± s.e.m. P-values are indicated. Sample numbers for (E and F) (n = 152); (G), non-progressors (n = 25) and progressors (n = 12). Download figure Download PowerPoint SOX9 index correlates with severity of liver fibrosis in patients and predicts progression We used the above profiles to construct a SOX9 index of positive nuclei per surface area of biopsy. We counted the biliary, HSC/Hep, and total SOX9+ populations in 152 biopsies. While there was no change in SOX9+ biliary cells at different stages of fibrosis, the HSC/Hep SOX9 index doubled as fibrosis severity increased; a finding which was also reflected in the total count (Fig 1E). HSC/Hep and total SOX9 indices from the initial biopsies correlated very strongly with the increment in Ishak fibrosis stage between initial and follow-up biopsies, while the biliary count did not alter (Fig 1F). The HSC/Hep SOX9 index was progressively higher for those patients whose liver fibrosis worsened over the subsequent 3 years. To see whether we could detect mild disease that was destined to progress, we identified all patients whose initial biopsy was IS0-2 and classified them into two groups: “progressors” (n = 12), defined by a worsening fibrosis at follow-up biopsy of ≥ 2 Ishak stages; or “non-progressors” (n = 25) where the fibrosis either improved was static or worsened by no more than one stage. Patients across the two groups had not received anti-HCV treatment, showed no significant difference in age, gender, alcohol consumption, ethnicity, serum alanine aminotransferase (ALT), necroinflammation, or HCV genotype (Appendix Table S1). In contrast, the HSC/Hep SOX9 index was significantly increased, more than double, in the initial biopsy of the “progressors” compared to “non-progressors” (P < 0.01; Fig 1G). The potential to predict future progression was analyzed by calculating the area under the receiver operating characteristic curve (AUROC). The ideal test would have an AUROC of 1, where a random guess would have an AUROC of 0.5. The HSC/Hep SOX9 index (AUROC = 0.895, P < 0.001), and consequently the total SOX9 index (AUROC = 0.910, P < 0.05), forecast significant worsening of fibrosis amongst patients in the “progressor” category (Fig 1H). Moreover, when the initial biopsy was subdivided into individual Ishak stages (rather than an amalgamated IS0-2) or into gender, the total SOX9 index significantly predicted progression in each instance except for patients at IS2 where low numbers were limiting (Appendix Table S2). We determined positive and negative predictive values (PPV and NPV) around the mean SOX9 count for total, HSC/Hep, and biliary populations (Fig 1I–K). The HSC/Hep and total SOX9 indices were predictive (Fig 1I and J), while the biliary count was unhelpful (Fig 1K). For additional comparison, we also quantified necroinflammation (NI) using the 0–18 scale of minimal (1–3), mild (4–8), moderate (9–12), and severe (13–18) NI (Ishak et al, 1995). The mean NI score in the initial biopsy was 2.75. Applying this threshold gave a PPV of 67% (NPV 63%). Setting the threshold at the upper limit of mild NI (score = 8) excluded all except one patient (Fig 1L; i.e., less predictive than the HSC/Hep and total SOX9 indices). Univariate logistic regression analysis identified age, the HSC/Hep (or total) SOX9 count, and NI to be significant risk factors in disease progression (Table 1; P < 0.05). However, when adjusted for time between biopsies using multivariate analysis, only age and the SOX9 index retained significance. The odds ratios indicated that each 1-year increase in age was associated with a 4% increase in the risk of becoming a “progressor”, whereas each cell increase in either the HSC/Hep or total SOX9 index increased the risk of fibrosis progression by 12% (Table 1). Male gender, serum ALT levels, or NI at first biopsy did not associate significantly with fibrosis progression. Table 1. Logistical regression analysis indicating risk factor association with progression of liver fibrosis Predictor Odds ratio (95% CI) Unadjusted Adjusted for age Adjusted for time to progression Age, per year increase 1.08 (1.00, 1.17)a – 1.04 (1.00, 1.08)a Age, > 55 versus ≤ 55 years 4.36 (0.36, 53.39) – – Gender, male versus female 3.09 (0.56, 17.17) 3.32 (0.50, 21.92) 2.87 (0.44, 18.70) Total Sox9, per unit increase 1.13 (1.04, 1.23)a 1.13 (1.03, 1.23)a 1.12 (1.03, 1.22)a Sox9 isolated cells, per unit increase 1.13 (1.04, 1.23)a 1.14 (1.04, 1.25)a 1.12 (1.03, 1.23)a Sox9 BD, per unit increase 1.14 (1.00, 1.29)a 1.14 (0.99, 1.31) 1.09 (0.95, 1.25) ALT, per unit increase 1.01 (0.99, 1.02) 1.01 (0.99, 1.02) 1.01 (0.99, 1.02) NI, per unit increase 1.63 (0.98, 2.71)a 1.55 (0.90, 2.68) 1.68 (0.94, 3.01) a Significant association (P < 0.05). Sox9 is induced in HSCs by liver injury and its loss protects against fibrosis and chronic inflammation To investigate the mechanism underlying SOX9 function in liver fibrosis, we explored the consequence of its loss in two well-established rodent models of the disease. Liver fibrosis was induced by carbon tetrachloride (CCl4) (with olive oil control) injections given twice weekly for 8 weeks to induce parenchymal disease or the bile duct ligated (BDL) to cause peribiliary fibrosis at 2 weeks. While SOX9 persisted in cholangiocytes, the nuclear transcription factor became detected in both models in a subset of HNF4α+ cells with large round nuclei scattered around the bile ducts, equivalent to the regenerative Heps observed in human tissue (Fig 2A and B, and Appendix Fig S1). SOX9 protein and mRNA were detected in αSMA-positive spindle-shaped cells in sections of li